Smith & Nephew plc (LON:SN) Given Average Rating of “Hold” by Brokerages

Shares of Smith & Nephew plc (LON:SNGet Free Report) have been assigned an average recommendation of “Hold” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is GBX 1,381.33.

SN has been the subject of several recent analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Berenberg Bank restated a “hold” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a research report on Friday, January 23rd. Panmure Gordon reaffirmed a “hold” rating and set a GBX 1,200 target price on shares of Smith & Nephew in a research note on Tuesday, December 9th. Royal Bank Of Canada downgraded Smith & Nephew to a “sector perform” rating and dropped their target price for the company from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Finally, Citigroup raised their price target on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a report on Friday, October 31st.

Get Our Latest Analysis on Smith & Nephew

Smith & Nephew Stock Performance

LON SN opened at GBX 1,371.50 on Friday. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The stock has a market cap of £15.04 billion, a PE ratio of 49.38, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The business’s fifty day moving average price is GBX 1,258.93 and its 200 day moving average price is GBX 1,303.60.

About Smith & Nephew

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

See Also

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.